EUVIMEDEUVIMED entdecken
Crossref

Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system

Haowen Tan iD, Xiubi Chen, Ying Chen, Xuan Ou, Tao Yang, Xida Yan

The Journal of Dermatology · 2025

DOI: 10.1111/1346-8138.17517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Haowen Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Office of Good Clinical Practice, Wuzhou Red Cross Hospital, Wuzhou, China. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to describe bullous pemphigoid (BP) associated with immune checkpoint inhibitors (ICIs) reported in the United States Food and Drug Administration adverse event reporting system (FAERS). We obtained reports of ICI‐associated BP from the first quarter of 2011 to the first quarter of 2024 in the FAERS database. The reporting odds ratio (ROR) method of the disproportionality analysis was performed to assess the potential risk for ICI‐associated BP. We also described the clinical characteristics of ICI‐associated BP and evaluated the time to onset (TTO) of BP developed after treatment with ICIs. Eight hundred and six cases of ICI‐associated BP were gathered, in which 56.58% of the patients were aged 65 years or older. The majority of patients were male, accounting for 68.49% of all cases. The prevalent potential cancer type was skin cancer (31.64%). The results of the disproportionality analysis showed that males (ROR = 2.10 [1.78–2.49]), patients aged 65 or older (ROR = 2.13 [1.79–2.55]), and patients with skin cancer (ROR = 2.08 [1.80–2.43]) were more likely to develop ICI‐associated BP. In comparison to cytotoxic T‐lymphocyte‐associated antigen 4 inhibitor and programmed cell death ligand 1 inhibitor, programmed cell death 1 inhibitor‐associated BP has a higher risk of development (ROR = 24.45 [22.52–26.56]). ICI‐associated BP had a median TTO of 204 days (interquartile range 57–426 days). ICI‐associated BP is a rare but important immune‐related adverse event. Our study provided helpful information to help medical professionals further understand ICI‐associated BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousImmune Checkpoint InhibitorsHumansMaleUnited StatesAgedFemaleRetrospective StudiesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationAged, 80 and overMiddle AgedSkin NeoplasmsAge FactorsSex Factors

Stichwörter der Autor:innen

FAERSbullous pemphigoiddata miningimmune checkpoint inhibitorspharmacovigilance

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Office of Good Clinical Practice, Wuzhou Red Cross Hospital, Wuzhou, China.
  • Center for Adverse Drug Reaction Monitoring of Mianyang, Mianyang, China.
  • Information Technology Center, Open University, Ziyang, China.
  • Department of Pharmacy, Central Hospital, Mianyang, China.

ORCID-Profile: Haowen Tan

Zitieren

APA

Tan, H., Chen, X., Chen, Y., Ou, X., Yang, T., & Yan, X. (2025). Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17517

Vancouver

Tan H, Chen X, Chen Y, Ou X, Yang T, Yan X. Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17517

BibTeX
@article{Tan2025,
  author = {Tan, Haowen and Chen, Xiubi and Chen, Ying and Ou, Xuan and Yang, Tao and Yan, Xida},
  title = {Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system},
  journal = {The Journal of Dermatology},
  year = {2025},
  doi = {10.1111/1346-8138.17517}
}
Kostenlos starten →